Progress on epigenetic alterations of peripheral T-cell lymphoma and its treatment

VernacularTitle:外周T细胞淋巴瘤表观遗传学改变及其治疗进展
Author: Haoyang PENG ^{1
,

2} ; Li GAO ; Jin WEI ; Xi ZHANG
Author Information

1. 川北医学院附属医院血液科,四川南充 637100
2. 陆军军医大学第二附属医院血液病医学中心,重庆 400037
Keywords: peripheral T-cell lymphoma; epigenetics; target agent; treatment; review
From: Chongqing Medicine 2024;53(13):2053-2058,2064
CountryChina
Language:Chinese
Abstract: Peripheral T-cell lymphoma(PTCL)is a group of hematological malignant tumors with high heterogeneity.At present,CHOP(cyclophosphamide,vincristine,prednisone,doxorubicin)or CHOP-like regimens are usually used for first-line treatment,but the remission rate is low,and the prognosis is poor.It is urgent to improve the traditional chemotherapy regimens to improve the efficacy onthe basis of tradtional che-motherapeutic regimen.Recent studies have found that the epigenetic alterations are crucial in the pathogene-sis of PTCL,and more and more new epigenetic targeted drugs have shown good effects and safety in the monotherapy and combination therapy of PTCL,which provide a new strategy for the precise diagnosis and treatment of PTCL.This article reviews the latest progress in epigenetic changes of PTCL and the prospects of targeted drug therapy applications,in order to provide reference for improving the clinical prognosis of the patients with PTCL.